You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Autoimmune Neutropenia After Kidney Transplantation: A Disregarded Entity of Posttransplant Neutropenia

Aubert, Olivier1; Sberro-Soussan, Rebecca1; Scemla, Anne1; Casadevall, Nicole3; Teyssandier, Irène3; Martinez, Frank1; Hermine, Olivier2; Legendre, Christophe1; Varet, Bruno2; De Fontbrune, Flore Sicre2,4

Transplantation:
doi: 10.1097/TP.0000000000000109
Rapid Communication
Abstract

Background: Neutropenia is common after kidney transplantation and is associated with an increased incidence of infections. Drug toxicities are the main causes of posttransplant neutropenia (PTN), mainly related to immunosuppressive drugs as mycophenolic acid (MPA) and anti-infectious agents, but some PTN remain unexplained.

Methods: Between January 2012 and January 2013, cultures of autologous granulocytic progenitors from bone marrow aspirate were performed in two patients with unexplained severe neutropenia.

Results: Both patients’ serum inhibited granulocytic differentiation while granulocytic differentiation was normal with the control serum. Similar inhibition of differentiation of granulocytic progenitors from a control marrow was observed with the patients’ serum as compared with the control serum. Moreover, in both cases intravenous immunoglobulins allowed full neutrophil count recovery. Other usual etiologies of acquired neutropenia including systemic drug toxicity, infection, and autoimmune disease were excluded. As frequently observed in adult immune neutropenia, granulocyte autoantibodies were absent in both cases. Owing to biological and clinical results, we concluded that an autoimmune mechanism was responsible for neutropenia. The levels of MPA, which is known to interact with tacrolimus, were not measured in our patients. However, the persistence of neutropenia more than 70 days after withdrawal of MPA did not support this hypothesis.

Conclusion: Autoimmune neutropenia should be considered in kidney transplant recipients in case of persistent unexplained neutropenia as it allows effective treatment and avoids the withdrawal of important immunosuppressive and anti-infectious treatments.

Author Information

1 Department of Kidney Transplantation, Hôpital Necker Enfants-Malades, Université Paris Descartes, AP-HP, Paris, France.

2 Department of Adult Haematology, Hôpital Necker Enfants-Malades, Université Paris Descartes, AP-HP, Paris, France.

3 Department of Haematology, Hôpital Saint-Antoine, Université Paris VI, AP-HP, Paris, France.

4 Address correspondence to: Flore Sicre de Fontbrune, M.D., M.Sc., Hôpital Saint Louis—Service d’Hématologie, Greffe de Moelle, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France.

The authors declare no funding or conflicts of interest.

E-mail: flore.sicre-de-fontbrune@sls.aphp.fr

O.A., R.S.-S., A.S., F.M., and F.S.d.F. participated in writing the paper and analyzing the data. N.C. and I.T. participated in performing cultures of granulocytic progenitors from bone marrow aspirate and analysis. O.H., B.V., and C.L. participated in data analysis.

Received 21 October 2013. Revision requested 5 November 2013.

Accepted 27 December 2013.

Accepted March 5, 2014

© 2014 by Lippincott Williams & Wilkins